FDA staff argue Avastin benefit in breast cancer not worth the risk
This article was originally published in Scrip
Executive Summary
At the first day - 28 June - of the much-anticipated two-day hearing on whether the USFDA should no longer allow Avastin (bevacizumab) from Roche's US arm Genentech to be sold for use in combination with paclitaxel to treat metastatic HER2 negative breast cancer, officials from the agency's Center for Drug Evaluation and Research (CEDR) made much the same arguments they advanced last July in persuading a panel of outside experts to recommend that the indication be dropped (scripintelligence.com, 21 July 2010).